Breast screening has increased the number of mastectomies

Breast Cancer Research

Volumn 11, Issue SUPPL. 3, 2009, Pages

  Dixon, J Michael ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LAPATANIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SCREENING; HUMAN; INTRADUCTAL CARCINOMA; MASTECTOMY; TUMOR VOLUME; BREAST; BREAST TUMOR; FEMALE; MASS SCREENING; METHODOLOGY; PATHOLOGY; STATISTICS;

BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASS SCREENING; MASTECTOMY;

EID: 77951903854     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2438     Document Type: Article

References (12)

1. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman P, . Consensus Conference Committee The consensus conference on the treatment of in situ ductal carcinoma of the breast, 22-25 April 1999. Cancer 2000, 88:946-954. 10.1002/(SICI)1097-0142(20000215)88:4<946::AID-CNCR26>3.0.CO;2-5, 10679665, Consensus Conference Committee.
2. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995, 76:1197-1200. 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0, 8630897.
3. Yen MF, Tabár L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of over diagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003, 39:1746-1754. 10.1016/S0959-8049(03)00260-0, 12888370.
4. Barnes NLP, Bundred NJ. Treatment of ductal carcinoma in situ. A Companion to Specialist Surgical Practice: Breast Surgery 2009, 175-192. Edinburgh: Saunders, Dixon JM.
5. Boland GP, Knox WF, Bundred NJ. Molecular markers and therapeutic targets in ductal carcinoma in situ. Microsc Res Tech 2002, 59:3-11. 10.1002/jemt.10172, 12242692.
6. Dixon JM, Faratian D, White S, Renshaw L, Murray J, Young O, Macaskill EJ, Williams L, Thomas J, Evans DB. DCIS and aromatase inhibitors. J Steroid Biochem Mol Biol 2007, 106:173-179. 10.1016/j.jsbmb.2007.05.015, 17604618.
7. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in the treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000. 10.1016/S0140-6736(99)05036-9, 10376613.
8. St Thomas J, Julian HS, Green RV, Cameron DA, Dixon JM. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 2007, 51:219-226. 10.1111/j.1365-2559.2007.02752.x, 17650216.
9. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carincoma in situ: trial design and preliminary results. Ann Surg Oncol 2003, 11:37S-43S.
10. Dixon JM, Renshaw L, Macaskill EJ, Young OE, Murray J, Cameron DA, Kerr GR, Evans DB, Miller WR. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 2009, 113:145-151. 10.1007/s10549-008-9915-6, 18264759.
11. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D. Phase II study of neoadjuvant docetexel, vinorelbine and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007, 25:1232-1238. 10.1200/JCO.2005.05.3306, 17296975.
12. Clough KB, Kaufman GJ, Nos C. Breast displacement techniques to increase resection volumes for breast-conserving surgery. A Companion to Specialist Surgical Practice: Breast Surgery 2009, 86-101. Edinburgh: Saunders, Dixon JM.